MetaCap

Solid Biosciences (SLDB) vs Surrozen (SRZN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Surrozen (SRZN) has outperformed Solid Biosciences (SLDB) over the past year, gaining 115.6% versus a gain of 33.0%. Over five years, SLDB leads with a -77.8% price change compared with -79.0% for SRZN. Solid Biosciences is the larger company by market cap ($697.6 million vs $596.4 million), about 1.2 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

SLDB+32.98%SRZN+115.61%
+167%+79%-9%
Nov 21, 20251 yearNov 20, 2026
SLDB-79.06%SRZN-79.38%
+7%-47%-101%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

SLDB versus SRZN key metrics
MetricSLDBSRZN
Share price$6.25$28.46
Market cap$697.57M$596.40M
1-day change-2.95%-7.21%
YTD return+10.82%+25.93%
1-year return+32.98%+115.61%
5-year return-77.78%-78.97%
EPS (TTM)$-1.76$-41.94
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$3.48M
Revenue growth (YoY)—-67.37%
Net income (latest FY)$-174.32M$-242.03M
Operating margin—-1210.58%
Net margin—-6960.77%
52-week high$11.45$37.83
52-week low$4.65$12.79
Distance from 52-week high-45.41%-24.77%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+199.36%+123.12%
Average volume1.30M537.16K
Shares outstanding111.61M20.96M
Employees12144
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • SRZN has outperformed SLDB by 82.6 percentage points over the past year.

About Solid Biosciences

SLDB stock →

Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 121 employees

About Surrozen

SRZN stock →

Surrozen, Inc., a biotechnology company, discovers and develops product candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the eye, intestine, liver, lung, retina, kidney, cochlea, cornea, skin, pancreas, and central nervous system.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 44 employees

SLDB vs SRZN FAQ

Which is bigger, Solid Biosciences or Surrozen?

Solid Biosciences (SLDB) is larger, with a market capitalization of $697.57M compared with $596.40M for Surrozen (SRZN).

Which stock has performed better over the past year, SLDB or SRZN?

SRZN returned +115.61% over the past 12 months, compared with +32.98% for SLDB (price return, excluding dividends). Past performance does not predict future results.

Are Solid Biosciences and Surrozen in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons